About Duchenne
Meet Colin, age 11. Amenable to exon 45 skipping

Duchenne muscular dystrophy: the most common muscular dystrophy in children.

What does it mean when a child is diagnosed with Duchenne muscular dystrophy (DMD)? Arming yourself with information about the cause and progression of this rare disease may help you make important decisions moving forward.

Understanding the cause and symptoms of Duchenne.

Duchenne muscular dystrophy is often referred to as DMD, or just Duchenne, and affects mostly boys. It is a progressive disease that causes muscle weakness that affects many parts of the body. Learn the common symptoms and the underlying cause behind this rare condition and why informed decision making at the earliest stages is so critical.
 

Learn More About DuchenneImage removed.

Graphic of DNA

Genes, dystrophin, and Duchenne.

Why are some children born with Duchenne? Putting it simply, Duchenne is caused by a genetic mutation that limits their body’s production of a protein called dystrophin. There is much more to learn about genetic mutations, including which specific mutations cause Duchenne, the role of dystrophin in muscle function, and why it’s so important to know your child’s specific mutation.
 

See How Genes Play a RoleImage removed.

Nicholas, age 12, amenable to exon 45 skipping and his family
doctor icon

The path to a Duchenne diagnosis.

Duchenne is initially suspected through a creatine kinase (CK) blood test. But too often, children who display symptoms of Duchenne are not given this simple test, delaying their diagnosis for years. While the CK test is a highly accurate indicator of Duchenne, genetic testing is required to confirm a diagnosis. The good news is that today’s genetic tests reveal far more information—including the exact mutation in the dystrophin gene—than those performed just a few years ago.
 

Get Details on DiagnosisImage removed.

doctor icon

Ongoing support and information from Sarepta.

Image
Vial icon

Receive future tips and support about treatment with AMONDYS 45.

Image
icon-signup-informed

Stay informed about SareptAssist services.

Image
meetings

Find out about patient resources that are available.

Image
signup

Get updates about news and research on Duchenne from Sarepta.

Read More

 

What is AMONDYS 45 (casimersen)?

AMONDYS 45 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the dystrophin gene that can be treated by skipping exon 45.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Read More

IMPORTANT SAFETY INFORMATION

Contraindications: Do not receive AMONDYS 45 if you are allergic to casimersen or any of the ingredients in AMONDYS 45. Serious allergic reactions to casimersen have included anaphylaxis, which may include difficulty breathing, tightness in the chest, and angioedema which may include swelling of the mouth, face, lips, or tongue.

Hypersensitivity Reactions: Serious allergic reactions, including angioedema and anaphylaxis, have occurred in patients who were treated with AMONDYS 45. Patients should seek immediate medical care should they experience signs and symptoms of allergic reactions. Your doctor will institute appropriate medical treatment which may include slowing, interrupting, or discontinuing the AMONDYS 45 infusion. Your doctor will monitor you until the condition resolves.

Kidney Toxicity and Monitoring: Damage to the kidneys was seen in animals who received casimersen. Although damage to the kidneys was not seen in clinical studies with AMONDYS 45, potentially fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.

Adverse Reactions: Side effects occurring in at least 20% of patients treated with AMONDYS 45 and at least 5% more frequently than in patients who received an inactive intravenous (IV) infusion were (AMONDYS 45, placebo): upper respiratory tract infection (65%, 55%), cough (33%, 26%), fever (33%, 23%), headache (32%, 19%), joint pain (21%, 10%), and pain in mouth and throat (21%, 7%).

Other side effects that occurred in at least 10% of patients treated with AMONDYS 45 and at least 5% more frequently than patients who received an inactive IV infusion were: ear pain, nausea, ear infection, pain after injury, and dizziness and light-headedness.

What do I do if I have side effects?

Ask your healthcare provider for advice about any side effects that concern you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

The information provided here does not include all that is known about AMONDYS 45. To learn more, talk with your healthcare provider.

Before receiving this infusion, please see the full Prescribing Information for AMONDYS 45 (casimersen).